Table 2.

Regression Analysis of HCT Outcomes

Univariate analysis			Excluding AML Patients
Outcome	HR (95% CI)	p-value	HR (95% CI)	p-value
Overall survival	0.68 (0.35–1.30)	0.24	0.73 (0.35–1.51)	0.39
Relapse	0.34 (0.12–0.94)	0.04	0.35 (0.12–1.01)	0.05
Non-relapse mortality	0.99 (0.41–2.34)	0.98	1.2 (0.43–3.31)	0.73
Relapse-free survival	0.62 (0.33–1.16)	0.14	0.66 (0.33–1.32)	0.23
Adjusted for cyto risk, IPSS, and donor
Outcome	HR (95% CI)	p-value	HR (95% CI)	p-value
Overall survival	0.87 (0.44–1.69)	0.68	0.9 (0.43–1.9)	0.79
Relapse	043 (0.15–1.20)	0.1	0.41 (0.14–1.2)	0.11
Non-relapse mortality	1.06 (0.45–2.54)	0.88	1.37 (0.49–3.82)	0.55
Relapse-free survival	0.72 (0.38–1.38)	0.32	0.78 (0.38–1.57)	0.48

^*Hazard Ratio (HR) reflects hazard of failure in group that received azacitidine relative to the hazard of failure in the group that received IC.